Compare CMRC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMRC | CHRS |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 177.7M |
| IPO Year | 2020 | 2014 |
| Metric | CMRC | CHRS |
|---|---|---|
| Price | $3.26 | $1.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.88 | ★ $5.51 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.43 | ★ 472.00 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $342,349,000.00 | N/A |
| Revenue This Year | $5.11 | $73.08 |
| Revenue Next Year | $4.50 | $30.94 |
| P/E Ratio | $52.50 | ★ N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $1.95 | $1.09 |
| 52 Week High | $5.55 | $2.62 |
| Indicator | CMRC | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 37.82 |
| Support Level | $2.58 | N/A |
| Resistance Level | $3.39 | $1.53 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 64.42 | 0.00 |
Commerce.com Inc is engaged in offering a Software-as-a-Service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which the majority of its revenue is generated from Americas-U.S.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.